HLA-mismatched unrelated donors are a viable alternate graft source for allogeneic transplantation following alemtuzumab-based reduced-intensity conditioning

Blood

Volumn 115, Issue 25, 2010, Pages 5147-5153

  Mead, Adam J ^a   Thomson, Kirsty J ^a   Morris, Emma C ^a   Mohamedbhai, Sajir ^a   Denovan, Shari ^a   Orti, Guillermo ^a   Fielding, Adele K ^a   Kottaridis, Panagiotis D ^a   Hough, Rachael ^a   Chakraverty, Ronjon ^a   Linch, David C ^a   Mackinnon, Stephen ^a   Peggs, Karl S ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; FLUDARABINE; MELPHALAN; ANTINEOPLASTIC AGENT; CANCER ANTIBODY; DRUG DERIVATIVE; HLA ANTIGEN; MONOCLONAL ANTIBODY; MYELOABLATIVE AGENT; VIDARABINE;

ADOLESCENT; ADULT; AGED; ALLOGRAFT; ALLOTRANSPLANTATION; ARTICLE; CLINICAL ARTICLE; CYTOMEGALOVIRUS INFECTION; CYTOPENIA; ENGRAFTMENT; FEMALE; GRAFT FAILURE; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA MATCHING; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; MALE; MORTALITY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; ACUTE DISEASE; BLOOD DISEASE; CHRONIC DISEASE; DISEASE FREE SURVIVAL; DRUG EFFECT; GRAFT SURVIVAL; HISTOCOMPATIBILITY; LIVING DONOR; LYMPHOCYTE DEPLETION; METHODOLOGY; MIDDLE AGED; RETROSPECTIVE STUDY; SURVIVAL RATE; TIME;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTINEOPLASTIC AGENTS; CHRONIC DISEASE; DISEASE-FREE SURVIVAL; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA ANTIGENS; HUMANS; INCIDENCE; LIVING DONORS; LYMPHOCYTE DEPLETION; MALE; MELPHALAN; MIDDLE AGED; MYELOABLATIVE AGONISTS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TIME FACTORS; TRANSPLANTATION CHIMERA; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; VIDARABINE;

EID: 77954664026     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-01-265413     Document Type: Article

References (26)

1. Craddock CF. Full-intensity and reduced-intensity allogeneic stem cell transplantation in AML. Bone Marrow Transplant. 2008;41(5):415-423. (Pubitemid 351386707)
2. Stein A, Forman SJ. Allogeneic transplantation for ALL in adults. Bone Marrow Transplant. 2008;41(5):439-446.
3. Morris EC, Mackinnon S. Reduced intensity allogeneic stem cell transplantation for low grade non-Hodgkin's lymphoma. Best Pract Res Clin Haematol. 2005;18(1):129-142. (Pubitemid 40197870)
4. Peggs KS, Anderlini P, Sureda A. Allogeneic transplantation for Hodgkin lymphoma. Br J Haematol. 2008;143(4):468-480.
5. Thomson KJ, Peggs KS. Role of allogeneic stem cell transplantation in multiple myeloma. Expert Rev Anticancer Ther. 2005;5(3):455-464. (Pubitemid 40894979)
6. Filipovich A. Hematopoietic cell transplantation for correction of primary immunodeficiencies. Bone Marrow Transplant. 2008;42(suppl 1):S49-S52.
7. van Rood JJ, Oudshoorn M. Eleven million donors in bone marrow donors worldwide! Time for reassessment? Bone Marrow Transplant. 2008;41(1):1-9.
8. Oudshoorn M, van Walraven SM, Bakker JN, et al. Hematopoietic stem cell donor selection: the Europdonor experience. Hum Immunol. 2006;67(6):405-412. (Pubitemid 44226305)
9. Petersdorf EW, Hansen JA, Martin PJ, et al. Major-histocompatibility- complex class I alleles and antigens in hematopoietic-cell transplantation. N Engl J Med. 2001;345(25):1794-1800.
10. Morishima Y, Sasazuki T, Inoko H, et al. The clinical significance of human leukocyte antigen (HLA) allele compatibility in patients receiving a marrow transplant from serologically HLA-A, HLA-B, and HLA-DR matched unrelated donors. Blood. 2002;99(11):4200-4206. (Pubitemid 35332066)
11. Lee SJ, Klein J, Haagenson M, et al. High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood. 2007;110(13):4576-4583. (Pubitemid 351377826)
12. Ho VT, Kim HT, Liney D, et al. HLA-C mismatch is associated with inferior survival after unrelated donor non-myeloablative hematopoietic stem cell transplantation. Bone Marrow Transplant. 2006;37(9):845-850.
13. Nakamae H, Storer BE, Storb R, et al. Low-dose total body irradiation and fludarabine conditioning for HLA-class I mismatched donor stem cell transplantation and immunological recovery in patients with hematological malignancies: a multicenter trial. Biol Blood Marrow Transplant. 2010;16(3):384-394.
14. Teshima T, Matsuo K, Matsue K, et al. Impact of human leucocyte antigen mismatch on graft-versus-host disease and graft failure after reduced intensity conditioning allogeneic haematopoietic stem cell transplantation from related donors. Br J Haematol. 2005;130(4):575-587. (Pubitemid 43899762)
15. Chakraverty R, Peggs K, Chopra R, et al. Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen. Blood. 2002;99(3):1071-1078. (Pubitemid 34525573)
16. Kottaridis PD, Milligan DW, Chopra R, et al. In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. Blood. 2000;96(7):2419-2425.
17. Chen YB, Spitzer TR. Current status of reduced-intensity allogeneic stem cell transplantation using alternative donors. Leukemia. 2008;22(1):31-41.
18. Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant. 1995;15(6):825-828.
19. Kahl C, Storer BE, Sandmaier BM, et al. Relapse risk in patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. Blood. 2007;110(7):2744-2748. (Pubitemid 47523200)
20. Petersdorf EW. HLA matching in allogeneic stem cell transplantation. Curr Opin Hematol. 2004;11(6):386-391. (Pubitemid 39491431)
21. Remberger M, Mattsson J, Hassan Z, et al. Risk factors for acute graft-versus-host disease grades II-IV after reduced intensity conditioning allogeneic stem cell transplantation with unrelated donors: a single centre study. Bone Marrow Transplant. 2008;41(4):399-405. (Pubitemid 351330736)
22. Ozawa S, Nakaseko C, Nishimura M, et al. Chronic graft-versus-host disease after allogeneic bone marrow transplantation from an unrelated donor: incidence, risk factors and association with relapse. a report from the Japan Marrow Donor Program. Br J Haematol. 2007;137(2):142-151. (Pubitemid 46474715)
23. Kawase T, Morishima Y, Matsuo K, et al. High-risk HLA allele mismatch combinations responsible for severe acute graft-versus-host disease and implication for its molecular mechanism. Blood. 2007;110(7):2235-2241. (Pubitemid 47523140)
24. Petersdorf EW, Anasetti C, Martin PJ, et al. Limits of HLA mismatching in unrelated hematopoietic cell transplantation. Blood. 2004;104(9):2976-2980. (Pubitemid 39434990)
25. Lim ZY, Ho AY, Ingram W, et al. Outcomes of alemtuzumab-based reduced intensity conditioning stem cell transplantation using unrelated donors for myelodysplastic syndromes. Br J Haematol. 2006;135(2):201-209. (Pubitemid 44401617)
26. Kroger N, Zabelina T, Binder T, et al. HLA-mismatched unrelated donors as an alternative graft source for allogeneic stem cell transplantation after antithymocyte globulin-containing conditioning regimen. Biol Blood Marrow Transplant. 2009;15(4):454-462.